Robert A. Anders
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 101
- Cancer Immunotherapy and Biomarkers 66
- Pancreatic and Hepatic Oncology Research 22
- CAR-T cell therapy research 16
- Co-authors
- Janis M. Taube (40 shared papers)Drew M. Pardoll (29 shared papers)Suzanne L. Topalian (19 shared papers)Duojia Pan (11 shared papers)Lieping Chen (8 shared papers)Haiying Xu (19 shared papers)Julie R. Brahmer (5 shared papers)Anirban Maitra (11 shared papers)
- Journals
- Journal of Clinical Oncology (22 papers)Cancer Research (11 papers)Cancer Immunology Research (10 papers)The American Journal of Surgical Pathology (9 papers)Journal of Clinical Investigation (8 papers)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Robert A. Anders
266 papers receiving 28.6k citations
Robert A. Anders's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 13.8k
- Immunology 7.4k
- Cell Biology 4.5k
- Hepatology 1.5k
- Cancer Research 2.5k
Countries citing papers authored by Robert A. Anders
This map shows the geographic impact of Robert A. Anders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Anders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Anders more than expected).
Fields of papers citing papers by Robert A. Anders
This network shows the impact of papers produced by Robert A. Anders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Anders. The network helps show where Robert A. Anders may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert A. Anders, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 274 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Hit paper breakdown → | 2010 | 2352 |
| 2 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Hit paper breakdown → | 2016 | 2066 |
| 3 | Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals Hit paper breakdown → | 2007 | 1887 |
| 4 | Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy Hit paper breakdown → | 2014 | 1885 |
| 5 | Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape Hit paper breakdown → | 2012 | 1685 |
| 6 | Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP Hit paper breakdown → | 2012 | 1143 |
| 7 | The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints Hit paper breakdown → | 2014 | 1126 |
| 8 | Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria Hit paper breakdown → | 2018 | 818 |
| 9 | The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals Hit paper breakdown → | 2010 | 621 |
| 10 | A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer Hit paper breakdown → | 2017 | 579 |
| 11 | 2008 | 452 | |
| 12 | 2007 | 441 | |
| 13 | Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody Hit paper breakdown → | 2012 | 429 |
| 14 | Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade Hit paper breakdown → | 2019 | 420 |
| 15 | 2014 | 407 | |
| 16 | 2016 | 365 | |
| 17 | PD-1 blockade in tumors with mismatch repair deficiency. Hit paper breakdown → | 2015 | 341 |
| 18 | 2014 | 318 | |
| 19 | 2011 | 302 | |
| 20 | 2013 | 293 |
About Robert A. Anders
Robert A. Anders is a scholar working on Oncology, Molecular Biology, Surgery, Hepatology and Immunology, having authored 274 papers that have together received 29.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (66 papers), Hepatocellular Carcinoma Treatment and Prognosis (27 papers), Immunotherapy and Immune Responses (27 papers), Pancreatic and Hepatic Oncology Research (22 papers), Immune Cell Function and Interaction (17 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers), Liver Disease Diagnosis and Treatment (16 papers) and CAR-T cell therapy research (16 papers). The work is most often cited by research in Oncology (13.8k citations), Immunology (7.4k citations), Cell Biology (4.5k citations), Hepatology (1.5k citations) and Cancer Research (2.5k citations). Robert A. Anders has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Janis M. Taube, Drew M. Pardoll, Suzanne L. Topalian, Duojia Pan, Lieping Chen, Haiying Xu, Julie R. Brahmer, Anirban Maitra, Jixin Dong and Tracee L. McMiller. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Cancer Immunology Research, The American Journal of Surgical Pathology and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.